Protocol Ledger

NCT03909971 · Phase II · COMPLETED

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Interventional Phase II clinical trial protocol NCT03909971 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-28 Enrollment: 109 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03909971
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)109 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03909971
Protocol FieldVerified Registry Value
NCT IdentifierNCT03909971
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment109 participants (ACTUAL)
Registered Start Date2019-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03909971
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI